Intraindividual variation (CV1)for glycohemoglobin (GHb) was estimated from serial measurements in patients with diabetes in either stable or variable clinical control. GHb determinations were performed by an affinity column procedure with an analytical imprecision of 4.9% (weighted average; GHb 8.2-14.7%). Within the groups of patients, both a short-(28-32 days) and long-term (-85 days) sampling protocol was used. The derived CV for each category was 4.2% (n = 16, stable, short-term), 7.1% (n = 23, stable, long-term), 5.1% (n = 13, variable, shortterm), and 9.8% (n = 21, variable, long-term 
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George Phillipou' and Patrick J. Phillips Intraindividual variation (CV1)for glycohemoglobin (GHb) was estimated from serial measurements in patients with diabetes in either stable or variable clinical control. GHb determinations were performed by an affinity column procedure with an analytical imprecision of 4.9% (weighted average; GHb 8.2-14.7%). Within the groups of patients, both a short-(28-32 days) and long-term (-85 days) sampling protocol was used. The derived CV for each category was 4.2% (n = 16, stable, short-term), 7 .1% (n = 23, stable, long-term), 5.1% (n = 13, variable, shortterm), and 9.8% (n = 21, variable, long-term). The mean GHb within each category was similar (-11%), and there was no statistically signfficant difference in GHb values
betweencategories. The resultsestablishthatthe CV1for
GHb is affected by both clinical control and the sampling time interval. These findings have importantimplications for the estimation of significantdifferences between serial GHb measurements and the sethng of appropriate analytical precision goals.
Indexing Terms:diabetes meihtus . assay imprecision Measurement of glycohemoglobin (Glib) derived from data on biological variation (4) (5) (6) (7) rather than the judgment of clinicians or health professionals (8, 9).
In this paper, we estimate biological variability and discuss appropriate analytical goals based on serial GHb data, measured by an affinity column method, from diabetic patients attending an outpatient clinic.
Materials and Methods

Materials.
The GlycoTest-l0O affinity mini-columns were purchased from Pierce Chemical Co., Rockford, IL. of the CV1 for Glib in patients with diabetes cannot be assumed to be similnr to the biological variation for nondiabetic subjects because the normal physiological glycemic regulatory processes are no longer operative. For diabetic subjects, glycemic control depends on management of hyperglycemia by diet, medication, insulin, or combinations thereof.
If the glycemic status of a subject steadily improves or deteriorates during the study period, not only will the CV, be increased because of the underlying trend, but the basic assumption of random, independent fluctuations around a homeostatic set point is no longer valid (4) . Particular importance was therefore placed in this study to exclude subjects whose serial Glib values had a significant trend (12) . We thank Hoffmsnn-La Roche and, in particular, G. Pater and L. Silverton, for their support of the original multicenter triaL The skilled technical assistance of S. K James and B. K. Farrant in performing the assays is gratefully acknowledged.
The level of clinical
The helpful comments of previous referees is acknowledged.
